【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於心衰竭之老年人。

抗血小板口服 Intermittent claudication

Inhibition of platelet aggregation (phosphodiesterase III inhibitor)

Onset of action: 2-4 weeks, may require up to 12 weeks
Bioavailability: 87-100%; high fat meal increases absorption
Protein binding: 95-98%
Metabolism: metabolized in liver primarily via CYP3A4 and lesser CYP2C19
Elimination half- life: 11-13 hr

hypersensitivity to cilostazol, CHF of any severity

C

Excretion in breast milk unknown/not recommended

Headache, dizziness, vertigo, diarrhea, infection, peripheral edema, palpitation, back pain, myalgia

Administration:
Give 30 min before or at least 2 hours after food
Dosage:
100 mg BID, dosage should be reduced to 50 mg twice daily during concurrent therapy with inhibitors of CYP3A4 or CYP2C19 (e.g., diltiazem, ketoconazole, itraconazole, erythromycin, omeprazole)